A Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belimumab Administered Subcutaneously in Adults With Interstitial Lung Disease (ILD) Associated With Connective Tissue Disease (CTD)
Latest Information Update: 30 May 2025
At a glance
- Drugs Belimumab (Primary)
- Indications Interstitial lung diseases
- Focus Registrational; Therapeutic Use
- Acronyms BEconneCTD-ILD
- Sponsors GSK
Most Recent Events
- 30 Aug 2024 New trial record
- 29 Aug 2024 Status changed from not yet recruiting to recruiting.